You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deal will join Fabric's genome annotation technology with Veritas' myGenome personal whole-genome sequencing service.
The company also announced that it is launching a new end-to-end clinical sequencing platform.
Congenica will use the proceeds to establish its presence in the US and China, where it will court not only clinical genetics labs, but specialists, academics, biotech, and pharma.
In addition to variant detection technology, Omicia also gets technologies like data compression, which will aid diagnostics development and data storage.
The institute recently launched rapid genome sequencing for critically ill newborns and plans to test genomic sequencing in several programs and clinical trials.
The institute will use Omicia's Opal Clinical system to achieve its goal of a 24-hour turnaround time for large-scale genome testing in its intensive care units.
Omicia will use the proceeds to accelerate product development, expand sales and marketing, and extend variations of its flagship Opal Clinical platform for NGS data analysis.
Congenica and Omicia have signed contracts to interpret data from the first 8,000 patients in the UK's 100,000 Genomes Project.
Genomics England has selected Congenica, Omicia, NantHealth, and WuXi Nextcode to provide clinical interpretation services for rare diseases and cancer
The company makes tests with rapid time-to-results intended for high-volume hospital and pathology labs using its proprietary diagnostic technology, 3Base.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
In Nature this week: the largest known collection of human genetic variants, and more.